Public space
Understand
AB SCIENCE
Discover a clear overview of AB SCIENCE, its development programs and useful information for patients, families, individual shareholders and the general public.
Understand
Development programs
Programs explained simply
Masitinib
Masitinib is AB SCIENCE’s most advanced tyrosine kinase inhibitor, developed in four priority indications.
AB8939
AB SCIENCE’s second molecule, AB8939 is being developed in acute myeloid leukemia (AML).
Discover AB SCIENCE’s complete pipelineView the pipeline
Drug development
From preclinical development to phase 3: program positions
1PreclinicalEvaluate the molecule before trials in humans
2Phase 1Assess safety and determine the dose
3Phase 2Explore efficacy and tolerability
4Phase 3Confirm findings in a larger population
MasitinibSickle cell diseasePhase 1
AB8939Acute myeloid leukemiaPhase 1/2
MasitinibAlzheimer’s disease
Amyotrophic lateral sclerosis
Progressive forms of multiple sclerosisPhase 3
Amyotrophic lateral sclerosis
Progressive forms of multiple sclerosisPhase 3
Explore essential information
Shareholder Information
Understand the company’s potential and access key information about AB SCIENCE shares.